#CS1, an oral histone deacetylase inhibitor developed by #CerenoScientific, has received #FastTrack designation from the @fda.gov for the treatment of pulmonary arterial hypertension (#PAH), the company announced.
Read more: https://bit.ly/3KORNyB
#RareDisease #Pulmonology #MedSky #RareSky
Read more: https://bit.ly/3KORNyB
#RareDisease #Pulmonology #MedSky #RareSky
CS1 Granted FDA Fast Track Designation for PAH Treatment
CS1, an oral histone deacetylase inhibitor, has received Fast Track designation from the FDA for the treatment of pulmonary arterial hypertension.
bit.ly
October 1, 2025 at 5:10 PM
Everybody can reply
1 likes
Cereno Scientific secures FDA Fast Track designation for its PAH drug CS1, advancing toward a Phase IIb trial. A key step in bringing new treatment options to patients with urgent unmet needs. 🚀💊
#News #FDAFastTrack #PAH #Biotech #RareDisease #DrugDevelopment #CerenoScientific
#News #FDAFastTrack #PAH #Biotech #RareDisease #DrugDevelopment #CerenoScientific
US FDA fast-tracks Cereno Scientific’s PAH drug CS1
Cereno Scientific is preparing for a global Phase IIb trial for CS1, scheduled to begin in the first half of 2026.
druganddeviceworld.com
August 27, 2025 at 7:52 PM
Everybody can reply
Cereno Scientific secures FDA Fast Track designation for its PAH drug CS1, advancing toward a Phase IIb trial. A key step in bringing new treatment options to patients with urgent unmet needs. 🚀💊
#News #FDAFastTrack #PAH #Biotech #RareDisease #DrugDevelopment #CerenoScientific
#News #FDAFastTrack #PAH #Biotech #RareDisease #DrugDevelopment #CerenoScientific
US FDA fast-tracks Cereno Scientific’s PAH drug CS1
Cereno Scientific is preparing for a global Phase IIb trial for CS1, scheduled to begin in the first half of 2026.
druganddeviceworld.com
August 27, 2025 at 7:52 PM
Everybody can reply
Armed with positive topline results from its Phase I trial, Cereno plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.
#news #CerenoScientific #CS014 #FibrosisResearch #IPF #PulmonaryFibrosis #ClinicalTrials #BiotechNews
#news #CerenoScientific #CS014 #FibrosisResearch #IPF #PulmonaryFibrosis #ClinicalTrials #BiotechNews
Cereno’s IPF drug clears Phase I, paving way for Phase II
The company plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.
druganddeviceworld.com
July 22, 2025 at 11:28 AM
Everybody can reply
1 reposts
Armed with positive topline results from its Phase I trial, Cereno plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.
#news #CerenoScientific #CS014 #FibrosisResearch #IPF #PulmonaryFibrosis #ClinicalTrials #BiotechNews
#news #CerenoScientific #CS014 #FibrosisResearch #IPF #PulmonaryFibrosis #ClinicalTrials #BiotechNews
Cereno’s IPF drug clears Phase I, paving way for Phase II
The company plans to start Phase II trial for HDAC inhibitor CS014 as a treatment for idiopathic pulmonary fibrosis (IPF) in H1 2026.
druganddeviceworld.com
July 22, 2025 at 11:28 AM
Everybody can reply
1 reposts
Sjukt lovande! #cerenoscientific www.biostock.se/2025/02/ytte...
Ytterligare data stärker Cerenos CS1 i PAH
26 februari, 2025Efter lovande fas IIa-resultat för läkemedelskandidaten CS1 mot pulmonell arteriell hypertension (PAH) i oktober 2024, levererar Cereno Scientific nu fullständiga data som stärker kan...
www.biostock.se
February 26, 2025 at 2:00 PM
Everybody can reply
Äntligen rör det på sig i aktien jag är ::host: ohälsosamt :host: hårt investerad i…kom igen nu #cerenoscientific
February 26, 2025 at 1:59 PM
Everybody can reply